Literature DB >> 20588259

Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model.

Atique U Ahmed1, Cleo E Rolle, Matthew A Tyler, Yu Han, Sadhak Sengupta, Derek A Wainwright, Irina V Balyasnikova, Ilya V Ulasov, Maciej S Lesniak.   

Abstract

Oncolytic adenoviral virotherapy is an attractive treatment modality for cancer. However, following intratumoral injections, oncolytic viruses fail to efficiently migrate away from the injection site and are rapidly cleared by the immune system. We have previously demonstrated enhanced viral delivery and replicative persistence in vivo using human bone marrow-derived mesenchymal stem cells (MSCs) as delivery vehicles. In this study, we evaluated the immune response to adenovirus (Ad)-loaded MSCs using the semipermissive cotton rat (CR) model. First, we isolated MSCs from CR bone marrow aspirates. Real-time quantitative PCR analysis revealed that CR MSCs supported the replication of Ads in vitro. Moreover, we observed similar levels of suppression of T-cell proliferation in response to mitogenic stimulation, by MSCs alone and virus-loaded MSCs. Additionally, we found that MSCs suppressed the production of interferon-γ (IFN-γ) by activated T cells. In our in vivo model, CR MSCs enhanced the dissemination and persistence of Ad, compared to virus injection alone. Collectively, our data suggest that the use of MSCs as a delivery strategy for oncolytic Ad potentially offers a myriad of benefits, including improved delivery, enhanced dissemination, and increased persistence of viruses via suppression of the antiviral immune response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20588259      PMCID: PMC2951553          DOI: 10.1038/mt.2010.131

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  27 in total

1.  Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.

Authors:  E M Horwitz; K Le Blanc; M Dominici; I Mueller; I Slaper-Cortenbach; F C Marini; R J Deans; D S Krause; A Keating
Journal:  Cytotherapy       Date:  2005       Impact factor: 5.414

2.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

3.  Multilineage potential of adult human mesenchymal stem cells.

Authors:  M F Pittenger; A M Mackay; S C Beck; R K Jaiswal; R Douglas; J D Mosca; M A Moorman; D W Simonetti; S Craig; D R Marshak
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

4.  Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.

Authors:  Zeng B Zhu; Sharmila K Makhija; Baogen Lu; Minghui Wang; Angel A Rivera; Sangae Kim-Park; Ilya V Ulasov; Fen Zhou; Ronald D Alvarez; Gene P Siegal; David T Curiel
Journal:  Int J Oncol       Date:  2005-07       Impact factor: 5.650

5.  Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential.

Authors:  Alexandra Peister; Jason A Mellad; Benjamin L Larson; Brett M Hall; Laura F Gibson; Darwin J Prockop
Journal:  Blood       Date:  2003-10-30       Impact factor: 22.113

6.  A new animal model for human respiratory tract disease due to adenovirus.

Authors:  D L Pacini; E J Dubovi; W A Clyde
Journal:  J Infect Dis       Date:  1984-07       Impact factor: 5.226

7.  Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.

Authors:  Adam M Sonabend; Ilya V Ulasov; Matthew A Tyler; Angel A Rivera; James M Mathis; Maciej S Lesniak
Journal:  Stem Cells       Date:  2008-01-10       Impact factor: 6.277

8.  Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.

Authors:  Ilya V Ulasov; Zeng B Zhu; Matthew A Tyler; Yu Han; Angel A Rivera; Andrey Khramtsov; David T Curiel; Maciej S Lesniak
Journal:  Hum Gene Ther       Date:  2007-07       Impact factor: 5.695

9.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.

Authors:  Mauro Krampera; Sarah Glennie; Julian Dyson; Diane Scott; Ruthline Laylor; Elizabeth Simpson; Francesco Dazzi
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

10.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

View more
  34 in total

Review 1.  Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

2.  The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.

Authors:  Christopher A Alvarez-Breckenridge; Jianhua Yu; Richard Price; Min Wei; Yan Wang; Michal O Nowicki; Yoonhee P Ha; Stephen Bergin; Christine Hwang; Soledad A Fernandez; Balveen Kaur; Michael A Caligiuri; E Antonio Chiocca
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.

Authors:  Atique U Ahmed; Matthew A Tyler; Bart Thaci; Nikita G Alexiades; Yu Han; Ilya V Ulasov; Maciej S Lesniak
Journal:  Mol Pharm       Date:  2011-06-30       Impact factor: 4.939

4.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

Review 5.  Engineering Stem Cells for Biomedical Applications.

Authors:  Perry T Yin; Edward Han; Ki-Bum Lee
Journal:  Adv Healthc Mater       Date:  2015-03-13       Impact factor: 9.933

6.  N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy.

Authors:  Chung Kwon Kim; Atique U Ahmed; Brenda Auffinger; Ilya V Ulasov; Alex L Tobias; Kyung-Sub Moon; Maciej S Lesniak
Journal:  Mol Ther       Date:  2013-07-25       Impact factor: 11.454

Review 7.  The art of gene therapy for glioma: a review of the challenging road to the bedside.

Authors:  Alex Tobias; Atique Ahmed; Kyung-Sub Moon; Maciej S Lesniak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-19       Impact factor: 10.154

Review 8.  The challenge for gene therapy: innate immune response to adenoviruses.

Authors:  Bart Thaci; Ilya V Ulasov; Derek A Wainwright; Maciej S Lesniak
Journal:  Oncotarget       Date:  2011-03

Review 9.  Stem cell-based therapies for cancer treatment: separating hope from hype.

Authors:  Daniel W Stuckey; Khalid Shah
Journal:  Nat Rev Cancer       Date:  2014-09-01       Impact factor: 60.716

10.  Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.

Authors:  Maria Bunuales; Eva Garcia-Aragoncillo; Raquel Casado; José Ignacio Quetglas; Sandra Hervas-Stubbs; Sergia Bortolanza; Carolina Benavides-Vallve; Carlos Ortiz-de-Solorzano; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Hum Gene Ther       Date:  2012-10-26       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.